文献速递皮肤肿瘤

薄溃疡性黑色素瘤预后不良及其对更积极治疗策略的启示

Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment.
PubMed 文献 · J Am Acad Dermatol · 2019-01-14

该研究基于加州癌症登记处2004至2013年确诊的43,008例非西班牙裔白人皮肤黑色素瘤患者,分析美国癌症联合委员会T1期(厚度小于1毫米)薄黑色素瘤的生存差异。结果显示,薄溃疡性肿瘤患者12个月生存率约为92.5%,低于薄非溃疡性患者的98.2%,24个月差异扩大至85.2%对96.1%,60个月差异超过15%。作者认为薄溃疡性肿瘤生存较差,提示需进一步研究更积极治疗的潜在获益。

要点

  • 薄溃疡性黑色素瘤患者12个月生存率约为92.5%,低于薄非溃疡性患者的98.2%。
  • 24个月生存率薄溃疡性为85.2%,薄非溃疡性为96.1%,差异较12个月扩大。
  • 60个月时薄溃疡性与薄非溃疡性患者生存差异超过15%。

核心结论

  • 厚度小于1毫米的溃疡性黑色素瘤患者生存较差,提示需进一步研究更积极治疗的潜在获益。

研究设计与样本

  • 基于人群的系列研究,纳入加州癌症登记处2004至2013年确诊的43,008例非西班牙裔白人皮肤黑色素瘤患者。
  • 采用Kaplan-Meier法估计生存结局,Cox比例风险模型估计死亡风险。

主要发现

  • 薄溃疡性肿瘤患者生存与II期肿瘤患者相当,而II期患者目前接受更积极的治疗。
  • 12个月时,薄溃疡性肿瘤患者生存率约为92.5%(95%CI 90.6%-93.9%),薄非溃疡性患者为98.2%(95%CI 98.0%-98.3%)。
  • 24个月时,薄溃疡性肿瘤患者生存率为85.2%(95%CI 82.8%-87.4%),薄非溃疡性患者为96.1%(95%CI 95.8%-96.3%)。
  • 60个月时,薄溃疡性与薄非溃疡性患者之间生存差异超过15%。

局限性

  • 既往癌症登记数据报告已注意到薄肿瘤存在一定程度编码错误的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical guidelines for the treatment of melanoma are based largely on the behavior of thicker tumors. As a result, little is known about survival differences among patients with thinner tumors. OBJECTIVE: To investigate the variability in survival for American Joint Committee on Cancer stage T1 thin melanoma tumors, defined as tumors less than 1 mm thick at diagnosis. METHODS: This population-based series included 43,008 non-Hispanic whites in whom cutaneous melanoma was diagnosed between 2004 and 2013 from the California Cancer Registry. Survival outcomes were estimated using the Kaplan-Meier method. Cox proportional hazard models were used to estimate risk of death. RESULTS: Survival for patients with thin ulcerated tumors was comparable to that for patients with stage II tumors, who are currently treated more aggressively. At 12 months, patients with thin ulcerated tumors had approximately 6% lower survival (92.5% [95% confidence interval (CI), 90.6%-93.9%]) compared with patients with thin nonulcerated tumors (98.2% [95% CI, 98.0%-98.3%]). At 24 months, this survival difference increased (85.2% [95% CI, 82.8%-87.4%] vs 96.1% [95% CI, 95.8-96.3%] for those with thin ulcerated and thin nonulcerated tumors, respectively) and a greater than 15% survival difference was seen at 60 months. LIMITATIONS: Previous reports of cancer registry data have noted some evidence of miscoding of thin tumors. CONCLUSION: The poorer survival in patients with ulcerated tumors less than 1 mm thick implies the need for additional studies to determine potential benefits of more aggressive treatment.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Hawkins ML, Rioth MJ, Eguchi MM, et al. Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment. J Am Acad Dermatol. 2019. PMID: 30654077. doi:10.1016/j.jaad.2019.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。